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Abstract 
  Research shows that adequate pain control is associated with increased patient 
satisfaction, faster rehabilitation, mobilization, reduced hospital stays, and ultimately decreased 
hospital costs.  Due to the many disadvantages of opioids, such as ileus, nausea, vomiting, 
respiratory depression, tolerance, and physical dependence, there has been a push for opioid-
sparing and multimodal analgesia perioperatively.  The purpose of this paper is to compare two 
local anesthetics, bupivacaine and Exparel (liposomal bupivacaine).  The use of these drugs in 
various regional techniques, specifically for total knee arthroplasty (TKA) and abdominal 
surgeries, will be discussed.  
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Exparel versus Bupivacaine: Outcomes, Advantages, and Costs 
The articles listed throughout this manuscript were found using the search engines 
CINAHL Complete, PubMed, and Google Scholar.  The keywords utilized were regional 
anesthesia, Exparel, and liposomal bupivacaine. 
Regional anesthesia is one way to limit opioid administration while still providing quality 
analgesia.  With the advancements in ultrasound imaging over the past several years, regional 
anesthesia has become safer and more efficacious.  Ultrasound allows the provider to visualize 
the target nerve directly and thus avoid accidental puncture of blood vessels and damage to 
nerves.  Ultrasound usage has also been linked to shorter procedure times.  The purpose of this 
research paper is to compare the use of bupivacaine to Exparel.  Several outcomes will be 
considered including postoperative pain, opioid requirements, length of hospital stay (LOS), 
patient outcomes, and cost. 
Bupivacaine 
  Bupivacaine is an amide local anesthetic.  It works by decreasing the permeability of 
sodium ions through the neuronal membrane, thereby blocking the initiation and conduction of 
nerve impulses and inhibiting depolarization.  Its onset of action is dependent on the route of 
administration.  Contraindications to the use of bupivacaine include obstetrical paracervical 
blocks and Bier blocks. When infiltrated for peripheral nerve blocks, the onset of action is two to 
ten minutes and the peak time is thirty to forty-five minutes. Bupivacaine is 84-95% protein 
bound. It is metabolized via the liver. The half-life of bupivacaine is age-dependent ranging from 
2.7 hours in adults to 8.1 hours in neonates. Bupivacaine is excreted via the urine (Bupivacaine: 
Drug information, n.d.).  
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The cost of Bupivacaine is variable based on specific concentrations and other additives. 
In a breast augmentation study conducted by Nadeau, Saraswat, Vasko, Elliott, and Vasko 
(2015), the cost of 20 mL of bupivacaine was $1.15, compared to $285 for 20 mL of liposomal 
bupivacaine.  
Exparel (Liposomal Bupivacaine) 
Exparel is a local anesthetic that uses DepoFoam drug delivery technology to encapsulate 
bupivacaine into multivesicular liposomes. Bupivacaine is released over time as the lipid 
membranes are reorganized in the human body (Exparel, 2019). The onset of Exparel is rapid. 
The duration of action is up to 72 hours, however systemic plasma levels can persist for 96 hours 
after administered locally, and 120 hours after administered into the brachial plexus for an 
interscalene nerve block. Exparel peaks twice. The initial peak is at one hour and the second 
peak occurs at 12 to 36 hours.  Exparel is 95% protein-bound and is metabolized primarily via 
hepatic conjugation, therefore it should be administered cautiously to patients with hepatic 
disease. It is excreted via the urine. The elimination half-life is 13-34 hours (Liposomal 
Bupivacaine: Drug Information, n.d.).  
Exparel has been approved for single-dose infiltration for postsurgical local analgesia in 
adults and interscalene brachial plexus nerve blocks. It has not yet been approved for other nerve 
blocks. Exparel should not be administered with other local anesthetics because bupivacaine may 
be immediately released leading to a higher potential for toxicity. It is safe to inject Exparel 
twenty minutes after lidocaine has been administered into the same location. Other forms of 
bupivacaine should not be administered within 96 hours of the administration of Exparel 
(Change the face of postsurgical recovery, 2019). To maintain Exparel's structural integrity, no 
needle smaller than 25 gauge should be used for administration (Exparel, 2019). 
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Exparel is contraindicated in paracervical blocks in obstetric patients. It is not 
recommended for use in patients under eighteen years old, or in pregnant patients due to the risk 
of fetal bradycardia and death. Exparel is not recommended for epidural, intrathecal, 
intravascular, intra-articular use, or regional nerve blocks other than interscalene brachial plexus 
blocks. It is currently being researched in several other surgeries including bariatric, breast, 
colorectal, general, obstetrics and gynecology, oral and maxillofacial, orthopedic, and spine. 
Adverse central nervous system (CNS) effects that can occur following Exparel administration 
include unconsciousness, respiratory arrest, and convulsions. Signs of CNS toxicity include 
restlessness, incoherent speech, circumoral numbness and tingling, metallic taste, twitching, 
tinnitus, blurred vision, dizziness, and drowsiness. Toxic concentrations can lead to 
cardiovascular changes including decreased cardiac output, hypotension, atrioventricular block, 
ventricular arrhythmias and cardiac arrest (Liposomal Bupivacaine: Drug Information, n.d.). The 
current cost of Exparel is listed as $21.01 per mL (1.3%) (Liposomal Bupivacaine: Drug 
Information, n.d.). 
Literature Review 
The use of liposomal bupivacaine in periarticular injections 
Schroer, Diesfeld, LeMarr, Morton, and Reedy (2015) 
  Local anesthetics can be injected around joints for analgesia. Periarticular blocks are 
advantageous because the surgeon can administer them intraoperatively, with no extra step 
required. Research has shown that by blocking pain receptors at the location of injury central 
sensitization can be avoided. Schroer, Diesfeld, LeMarr, Morton, and Reedy (2015) conducted a 
Level II prospective, randomized controlled trial involving 111 patients undergoing unilateral 
total knee arthroplasty (TKA). The study group consisted of fifty-eight patients who received 
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266 mg (20 mL) of liposomal bupivacaine (LB) with 75 mg (30 mL) of 0.25% bupivacaine via 
periarticular injection (PAI). The control group consisted of fifty-three patients who received 150 
mg (60 mL) of 0.25% bupivacaine via PAI. Spinal anesthesia was administered to both groups 
and consisted of 25 mcg fentanyl and 2 mL of 0.75% bupivacaine, followed by propofol for 
conscious sedation. Throughout the surgery 8 mg of dexamethasone, 8 mg ondansetron, and 10 
mg/kg of tranexamic acid (up to 1 gram) were administered. During the postoperative period, 
patients received 400 mg celecoxib daily and 20 mg OxyContin every 12 hours for 2 doses. 
Patient-Controlled analgesia (PCA) pumps delivering hydrocodone, oxycodone, and morphine 
were available for breakthrough pain.  
Results 
Primary measures of this study were pain scores obtained using the Visual Analog Scale 
(VAS). Secondary outcomes included length of hospital stay (LOS), knee flexion at discharge, 
knee flexion at three weeks, and narcotic use during hospitalization. The results of this study 
showed that pain scores were similar between both groups. On the morning of postoperative day 
(POD) 1 pain scores were 4.5 for the study group and 4.6 for the control group, (p = .73). On the 
afternoon of POD 1, pain scores were 4.1 and 4.5, (p = .28). On the morning of POD 2, pain 
scores were 4.4 and 4.8, (p = .27). On the afternoon of POD 2, pain scores were 4.1 and 4.6, (p = 
.23). On the morning of POD 3, pain scores were 3.9 and 4.1, (p = .57). The length of hospital 
stay was 2.9 for the study group versus 3.0 for the control group, (p = .98). At discharge, knee 
ROM was 81 degrees (study group) compared to 77 degrees (control group), (p = .14). Three 
weeks following surgery knee ROM was 107 degrees (study group) and 108 degrees (control 
group), (p = .47).  Narcotic requirements were slightly lower in the study group (51.8) compared 
to the control group (54.2), (p = .34). Five percent of patients in the study group experienced 
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postoperative nausea versus four percent in the control group, (p = .72) (Schroer, Diesfeld, 
LeMarr, Morton, and Reedy, 2015). 
The results of this study showed no substantial benefit of LB versus bupivacaine in 
periarticular injections for TKA. The use of LB did not result in improved pain scores, reduced 
narcotic use, or enhanced knee ROM during the hospital stay. Considering the results and the 
large cost difference between Exparel ($285) and bupivacaine ($2.80), the authors do not support 
the routine use of LB (Schroer et al., 2015).  
Limitations 
Several limitations exist in this study. The surgeon and the surgical team were not 
blinded to the technique used. Another limitation was the size of the study population. More than 
1000 patients are needed to attain a greater than or equal to 0.2 VAS difference (Schroer et al., 
2015). 
Liu et al. (2019) 
Liu et al. (2019) conducted a Level I meta-analysis of thirteen randomized controlled 
trials (RCTs) that examined liposomal bupivacaine (LB) to traditional PAIs. Traditional PAIs 
consisted of bupivacaine and a cocktail of either ropivacaine, epinephrine, ketorolac, or 
clonidine. The LB group consisted of 691 patients. The traditional PAI group included 682 
patients. The primary outcome of this study was postoperative pain using VAS. Secondary 
outcomes included opioid consumption (morphine equivalents), LOS, and adverse effects. The 
Cochrane Collaboration tool was utilized to assess bias risk.  
Results  
  The results of this study showed that postoperative pain using the VAS, at every period 
following TKA, was similar between both groups. During the first 24 hours following TKA, the 
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LB group had similar pain scores compared to the traditional PAI group, (p = .09). Pain scores 
during the second twenty-four hours following TKA were similar between both groups, (p = 
.12). Pain scores in the third twenty-four hours following TKA were similar between both 
groups, (p = .12). During the first twenty-four hours following TKA results showed that the LB 
group did not consume significantly fewer opioids compared to the traditional PAI group, (p = 
.45). During the second twenty-four hours following TKA, the LB group consumed significantly 
fewer opioids compared to the traditional PAI group, (p = .01). During the third twenty-four 
hours following TKA, the LB group also consumed significantly fewer opioids compared to the 
traditional PAI group, (p = .006).  The rates of postoperative nausea and vomiting (PONV) were 
lower in the LB group compared to the traditional PAI group, (p = .05), however, significance 
was not reached. LOS was not significantly longer in the LB group, (p = .50) (Liu et al., 2019). 
Limitations 
The first limitation was that not all of the RCTs included in this meta-analysis examined 
all outcomes. Therefore, the analysis only included a small sample. The authors explain that the 
RCTs could have been of better quality and more relevant to provide more worthwhile results. 
The various cocktails used amongst the different groups could have influenced the results. The 
last limitation mentioned was that functional recovery was not assessed amongst the groups. The 
authors recommend that future studies should focus on the most effective drug composition for 
periarticular injections. The same periarticular injection technique should be confirmed 
throughout all groups to reduce bias (Liu et al., 2019). 
Wang, Xiao, Wang, Zhao, and Ma (2017) 
Wang et al. (2017) conducted a Level I systemic review and meta-analysis comparing 
bupivacaine to liposomal bupivacaine in terms of safety and efficacy following TKA. Ultimately, 
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three RCTs and two Non-RCTs were included in this meta-analysis. Three studies used spinal 
anesthesia. The other studies used general anesthesia.  
Results 
Throughout 72 hours following surgery pain was reduced in the LB group (141.8) versus 
202.5 (p < 0.0001). Opioid consumption (morphine equivalents) on POD 1 were significantly 
higher in the control group. Opioid consumption was similar between both groups on POD 2 and 
3. On POD 1, significantly fewer opioids were needed in the group that received a LB-based 
multi-modal pain regimen (20 mg) than the bupivacaine group (112 mg), (p < 0.01). The LB 
group experienced lower rates of PONV. Ultimately, the findings presented within this meta-
analysis demonstrated that LB provided superior pain relief, decreased opioid consumption, and 
fewer side effects compared to periarticular injections of traditional bupivacaine (Wang, et al., 
2017).  
Limitations 
  Only five studies, with small sample sizes, were included in this meta-analysis. 
Functional outcomes were not considered due to scarce data. Anesthetic doses and pain 
management regimens were not standard throughout the studies. Another limitation of this study 
was a short follow-up period. The authors mention that in future studies the combined use of 
epinephrine, NSAIDs, and femoral nerve block (FNB) should be studied (Wang et al., 2017).  
Kuang et al. (2017)  
Kuang et al. (2017) conducted a Level I systematic review and meta-analysis comparing 
pain relief and functional recovery after TKA between patients who received Exparel via 
periarticular injection versus placebo or actual bupivacaine hydrochloride. Eleven studies were 
included in this meta-analysis. Four were RCTs, and seven were non-RCTs. The primary 
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outcome was VAS scores. The secondary outcome was opioid consumption (morphine 
equivalents) during hospitalization. Other outcomes examined included ROM, LOS, PONV, and 
ambulation distance. 
Results 
 Results showed that liposomal bupivacaine provided similar VAS scores at 24 hours (p = .46), 
48 hours (p = .43), and 72 hours (p = .21). Both groups also had similar total opioid consumption 
(p = .25), ROM (p = .28), LOS (p = .53), PONV (p = .34), and ambulation distance (p = .07). 
The authors of this study ultimately do not consider liposomal bupivacaine worthy, due to the 
significant cost difference (Kuang et al., 2017).  
  Limitations 
Only four RCTs were included in this meta-analysis. To increase the statistical value 
more should be included. The authors recommend longer follow-up periods in the future. Several 
potential causes of heterogeneity exist including variable liposomal bupivacaine dosages, 
anesthetic technique, PAI method, and the tourniquet (Kuang et al., 2017). 
Schwarzkopf et al. (2016) 
Schwarzkopf et al. (2016) conducted a Level III, comparative study including thirty-eight 
patients. The goal of this study was to determine whether or not LB resulted in better outcomes 
in patients with a history of chronic opioid use, compared to traditional PAIs. All patients had 
unilateral cemented TKA and resurfaced patella, through a medial parapatellar approach, 
performed by the same surgeon and technique. Patients were randomly assigned to either receive 
PAI with LB (n = 20) or standard PAI combination of ropivacaine, clonidine, ketorolac, 
epinephrine and saline (n = 18). Patients in the LB group received 20 mL of liposomal 
bupivacaine, 60 mL of saline, and 20 mL of 0.25% bupivacaine. Patients in the standard PAI 
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group received 0.5% ropivacaine (49.25 mL), 80 mg clonidine (0.8 mL), 30 mg Toradol (1 mL), 
0.5 mg epinephrine (0.5 mL), and 48 mL of saline. 
  Results 
Since patients with chronic pain have different narcotic tolerances baseline narcotic usage 
was considered preoperatively. Throughout the study postoperative narcotic use, average daily 
pain scores, and maximum daily pain scores were similar between both groups. When examining 
daily VAS scores separately, the LB group experienced higher scores in POD 1. There was no 
significant difference in first time opioid use in the recovery room between the LB group (4 
minutes) and the control group (24 minutes), (p = .2365). LOS was similar between both groups 
(p = .91). Ultimately LB was not found to be superior. The results of this study did not justify the 
increased cost (Schwarzkopf et al, 2016). 
Limitations 
This study could be improved with larger prospective trials. Another limitation of this 
study is the vastly different techniques used for periarticular injections. The authors suggest in 
the future that outcomes from several surgeons will help reduce bias in technique (Schwarzkopf 
et al., 2016).  
Smith et al. (2017) 
Smith et al. (2017) conducted a Level I double-blinded, RCT. The purpose of this study 
was to examine the outcomes associated with intraarticular bupivacaine hydrochloride via 
infusion catheters (ON-Q) versus periarticular injections of Exparel. Ninety-six patients were 
part of the ON-Q group. One hundred four patients were part of the Exparel group. The Exparel 
group received 266 mg LB (20 mL) and normal saline (40 mL). The primary outcome was 
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cumulative narcotic consumption on POD 0-3. This data was retrospectively gathered from 
hospital records. Once discharged, data was collected via patient surveys. 
Results 
Opioid consumption was gauged using morphine equivalents. On POD 0-3 the ON-Q 
group consumed, on average, 10.4 morphine equivalents compared to the Exparel group that 
averaged 10.9. This finding was not significant, (p = .641). On POD 0-3 patients in the ON-Q 
group rated their pain 3.6. The Exparel group rated their pain, on average, 4.0. This finding was 
insignificant, (p = .373). The maximum and minimum pain scores were similar between both 
groups on all postoperative days. The Exparel group reported that pain interfered with their 
ability to walk (4.6 points) more than the ON-Q group (3.5 points), (p = .019), which made this 
finding significant. Pain significantly impacted the Exparel group more (4.5 points) than the ON-
Q group (3.2 points), (p = .010). Twenty-two percent of patients in the ON-Q group suffered 
from bleeding or leakage around the pump. Due to this complication, five percent of the ON-Q 
group required catheter removal. Three percent of patients in the Exparel group required 
manipulation of the knee due to stiffness at 57 and 70 days postop, compared to five percent in 
the ON-Q group. There were no differences in LOS, patient satisfaction, complications, PONV, 
or constipation in either group. According to the authors of this study, Exparel was not proven to 
be superior to ON-Q. It is suggested that further research is needed to examine the complication 
rates and costs associated with continuous catheter infusions (Smith et al., 2017). 
Limitations 
Senior surgeons were to remain blinded, therefore they were unable to perform the 
injections. Although surgical assistants were trained regarding the proper way to administer 
Exparel, variations are possible. Exparel was not injected until after the site was closed, therefore 
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it was not possible to inject into the posterior of the capsule or the periosteum. This could lead to 
adverse results in the Exparel group. Another limitation was that long-term results were not 
acquired. The Exparel group had an imitation pump attached to their lower extremity, to remain 
blind. This could have possibly masked the mobility and comfort in the Exparel group. Lastly, to 
achieve the desired power of 0.8, 238 patients were needed for this study. This study only 
enrolled 200 patients (Smith et al., 2017). 
Alijanipour et al. (2017) 
A Level I RCT was conducted by Alijanipour et al. (2017) to compare liposomal 
bupivacaine (experimental group) to bupivacaine (control group). 162 patients who underwent 
primary TKA between January 2014 and May 2015 were included in this study. Seventy-five 
patients were randomly assigned to the control group and eighty-seven patients were assigned to 
the experimental group. Patients in the experimental group received 266 mg (20 mL) of 
liposomal bupivacaine with 40 mL of sterile normal saline and 0.5 mg epinephrine (0.5 mL). The 
control group received 50 mg of 0.25% bupivacaine (20 mL) with 1:200,000 epinephrine. This 
solution was diluted with 40 mL of normal saline. Postoperatively, all patients received identical 
surgical techniques, spinal anesthesia, pain management, and rehabilitation. The primary 
outcome of this study pain scores via VAS 96 hours postop. Secondary outcomes included 
opioid consumption (morphine equivalents), opioid-related side effects, patient satisfaction 
during the first 96 hours following surgery. Functional outcomes and complications were also 
evaluated.  
Results  
Preoperatively, the experimental group reported lower rates of average daily pain. The 
results of this study showed no differences in the least, worst, and average pain in either group. 
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Both groups experienced an increase in pain 6-12 hours postoperatively. After the peak, the 
control group did not experience a decline in pain until the morning of POD 2. There were no 
statistically significant differences between either group regarding postoperative pain scores on 
each day, opioid consumption (daily and overall), opioid-related side effects, surgical or medical 
complications, LOS, or patient satisfaction. Exparel did not result in improved outcomes 
(Alijanipour et al., 2017).  
Limitations 
Pain assessments were completed at 8 am and at 5 pm, regardless of the time of the 
surgical procedure, physical therapy, or administration of pain medication. These factors could 
have potentially influenced pain scores. The surgeons were not blinded while administrating the 
medication. After reviewing the findings, it was discovered that two patients did not meet 
inclusion criteria. One patient in the experimental group had a history of opioid addiction. One 
patient in the control group had many knee surgeries twenty years before this study regarding 
TKA (Alijanipour et al., 2017). 
Jain et al. (2016) 
  Jain et al. (2016) conducted a single-blinded, prospective, randomized study to examine 
outcomes between three groups, all undergoing TKA. Arm 1 consisted of patients who received 
intra-articular injections of 0.25% bupivacaine (30 mL) with epinephrine 1:200,000, and 10 mg 
of morphine at the end of the surgery. Arm 2 consisted of periarticular injections of 0.25% 
bupivacaine with epinephrine 1:200,000, and 10 mg of morphine. Arm 3 received a periarticular 
injection of liposomal bupivacaine.  Primary outcomes included average postoperative pain 
ratings for the entire hospital stay (using Wong-Baker pain faces scale). Secondary outcomes 
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included average in-hospital opioid intake (using morphine equivalents) and the cost of pain 
medications during hospital stay (perioperative and postoperative). 
Results 
There were no significant differences in average or maximum postoperative pain scores 
in either group. No significant differences were seen in morphine equivalents postoperatively. 
LOS in days were as follows: 1.3 (Arm 1), 1.2 (Arm 2), and 1.4 (Arm 3), (p = .09). Maximum 
pain scores were as follows: 5.85 (Arm 1), 5.81 (Arm 2), and 5.69 (Arm 3), (p = .92). Average 
pain scores were as follows: 3.95 (Arm 1), 3.97 (Arm 2), and 3.86 (Arm 3), (p = .94). Mean 
morphine equivalents (MME) per 24 hours were as follows: 100.7 (Arm 1), 100.1 (Arm 2), and 
98.9 (Arm 3), (p = .97).  The average cost of perioperative and postoperative pain management 
was significantly higher in Arm 3 (LB group) at an average of $402.09. Arm 1 totaled $15.99 
and Arm 2 totaled $23.21. The authors concluded that there was no benefit regarding the 
outcome or cost when using LB. An intraarticular injection of bupivacaine with morphine was 
proven to be as effective and required less time (Jain et al., 2016).  
Limitations  
The nursing and physical therapy staff were the same for all patients, which could 
potentially lead to bias. The surgeon and OR team could not be blinded to the treatment but were 
not permitted to analyze or collect any data. The short LOS could have caused some positive 
outcomes associated with Exparel to go unnoticed. The manufacturer's recommendations for 
Exparel were followed and no other local anesthetics were used in conjunction. Several surgeons 
have noted that adding plain bupivacaine to Exparel allows for analgesia during the 8 to 12 hour 
period, while liposomal bupivacaine is not yet in full effect (Jain et al., 2016).  
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Mont, Beaver, Dysart, Barrington, and Del Gaizo (2018) 
Mont et al. (2018) conducted a RCT comparing local infiltration of liposomal 
bupivacaine (LB) versus regular bupivacaine (without LB). Seventy patients received 266 mg 
liposomal bupivacaine (20 mL) and 0.5 % bupivacaine (20 mL) via local infiltration. Sixty-nine 
patients received 0.5% bupivacaine (20 mL) via local infiltration. Outcomes included pain, 
narcotic consumption, time to first narcotic rescue, the proportion of opioid-free patients, and 
safety.  
Results 
Average pain scores were significantly lower in the LB group (180.8) compared to the 
without LB group (209.3), (p = .0381). Total opioid consumption was significantly reduced in 
the LB group (18.7 mg) versus the without LB group (84.9 mg). Ninety percent of patients in the 
LB group required opioids, compared to 100% in the bupivacaine group. The time to first 
narcotic rescue was significantly longer in the LB (ranging from 0.25 to 48 hours) compared to 
0.27 to 33 hours (without LB) group. Ultimately, LB was associated with improved 
postoperative pain, reduced opioid consumption, increased time before first narcotic rescue, and 
more opioid-free patients (Mont et al., 2018).  
Limitations  
The moderate size of this study can be considered a limitation. The only rescue 
medications that were used were opioids. If non-opioids were also utilized as rescue medications, 
opioid use could potentially be further reduced.  Since all patients were required to stay in the 
hospital for two days, length of stay could not be examined. Another limitation to this study was 
the fact that healthcare costs and recovery time were not assessed (Mont et al., 2018).  
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Synder, Scheuerman, Gregg, Ruhnke, and Eten (2016) 
Snyder et al. (2016) organized a prospective, randomized, double-blind trial that 
compared postoperative pain scores in thirty-five patients who received liposomal bupivacaine 
(LB) versus thirty-five patients who received a concentrated cocktail injection in patients 
undergoing TKA. The liposomal bupivacaine group received 266 mg of bupivacaine with 0.9% 
normal saline (100 mL). The concentrated cocktail group received 30 mg ketorolac, 5 mg 
morphine, 0.6 mg epinephrine, 400 mg ropivacaine, and 0.9% normal saline (100 mL). 
Outcomes included post-op pain, opioid consumption (morphine equivalents), patient 
satisfaction with pain control, and adverse events. The surgeon responsible for the injection was 
blinded. Patients received either spinal anesthesia consisting of 0.75% ropivacaine or general 
anesthesia consisting of 1% propofol via a continuous infusion (Snyder et al., 2016).  
Results 
Patients in the LB group reported less pain in the PACU (2.68) compared to the 
concentrated cocktail group (2.87), (p = .033). Patients in the concentrated cocktail group 
experienced higher pain than the LB group, on POD 0, 1, and 2. Results could not be obtained on 
POD 3. Patients in the LB group required fewer narcotics in the PACU and on POD 0 through 2. 
Patient satisfaction was assessed using a 5 point Likert scale. Patients in the LB group 
experienced higher satisfaction with pain control while hospitalized (4.91 versus 4.11), (p = 
.0001). Overall pain satisfaction was also higher in the LB group (3.97 versus 4.57), (p = .001). 
Higher rates of nausea occurred in the concentrated cocktail group (19 versus 9), (p = .011). 
Ultimately, there was no significant difference in pain scores, opioid consumption, adverse 
effects, or patient satisfaction. There were fewer adverse events in the LB group (Snyder et al., 
2016).  
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Limitations  
Limitations of this study include the fact that postoperative pain scores cannot be 
generalized to all types of surgeries. Patients received different anesthesia techniques, neuraxial 
anesthesia versus general anesthesia, based on comorbidities. The authors of this study 
recommend that further research be completed to refine the differences in pain scores and patient 
satisfaction using various combinations of anesthesia and injection techniques (Snyder et al., 
2016).  
Zlotnicki et al. (2018)  
A randomized, blinded, prospective study was conducted on 118 patients comparing 
periarticular injections of liposomal bupivacaine to plain bupivacaine. Primary outcomes 
included pain relief, total opioid use, completion of physical therapy goals, and ROM. Patients, 
nurses and physical therapists were blinded. Patients in the liposomal bupivacaine group 
received 30 mL of liposomal bupivacaine mixed with 70 mL of normal saline (n = 38). Patients 
in the bupivacaine group received 20 mL of 0.5% bupivacaine with 70 mL of normal saline (n = 
40). The historical control group consisted of patients who did not receive periarticular injections 
but were enrolled in the preoperative and postoperative pain pathway (n = 40) (Zlotnicki et al., 
2018).  
Results 
The LB group experienced decreased pain during physical therapy at 24 hours postop 
(5.4), compared to the control group (7.3) and the plain bupivacaine group (6.9). Both 
periarticular groups had significantly improved ROM. On POD 1 the LB group was able to flex 
82.7 degrees, compared to 80 degrees in the plain bupivacaine group, and 66.4 degrees in the 
control group. Overall, LB did not result in significantly improved pain scores, ROM, or total 
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narcotic usage. Considering the cost difference of plain bupivacaine ($2.28) compared to LB 
($282.72), the authors do not support the use of LB (Zlotnicki et al., 2018). 
Limitations 
The use of a historical control group allowed for the LB group and the plain bupivacaine 
group to be blinded, however it did not allow all groups to be prospective. Another limitation 
was that there was no power analysis or calculation of sample size before the study was 
implemented. Also, no post hoc power analysis was performed to eliminate biased results 
(Zlotnicki et al., 2018). 
Bagsby, Ireland, and Meneghini (2014) 
Bagsby et al. (2014) conducted a Level III retrospective cohort study to compare 
liposomal bupivacaine to traditional PAI for unilateral primary TKA. Eighty-five patients 
received a traditional PAI of ropivacaine, epinephrine, and morphine. Sixty-five patients 
received PAI of liposomal bupivacaine. All patients received single-shot morphine spinal 
preoperatively, light general anesthesia, as well as a periarticular injection of either ropivacaine, 
morphine, epinephrine, or LB. To provide analgesia during the immediate postoperative period, 
before LB was effective, the periarticular tissues were infiltrated with 0.5% bupivacaine with 
1:200,000 epinephrine (30 mL). Postop pain scores were assessed every 2-4 hours using a VAS. 
The pain was also assessed at discharge. Patients received various doses of hydrocodone based 
on pain ratings. These values were then converted to opioid equivalents.  
Results  
Average pain scores from 24 hours postop until discharge were lower in the traditional 
group (4.4) compared to the LB group (4.9), which was statistically significant (p = .04). At 
discharge the pain scores were slightly higher in the traditional group (3.6) compared to 4.1 in 
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the LB group, this did not reach significance (p = .14). The results of this study did not show 
statistically different opioid requirements, average antiemetic requirements, or average naloxone 
doses. Ultimately, periarticular injections of LB resulted in inferior pain control at a higher 
expense. This could be due to the slow release of bupivacaine from the liposomes (Bagsby et al., 
2014).  
Limitations  
The first limitation of this study was that it was not randomized. The second limitation 
deals with the technique used during periarticular injections which can potentially skew the 
results. Several nurses administered analgesics and antiemetics and documented them. The 
authors recommend that prospective, RCTs be conducted in the future (Bagsby et al., 2014).  
Femoral nerve blocks with bupivacaine versus PAI using LB 
Yu, Szulc, Walton, Bosco, and Iorio (2016)  
Femoral nerve blocks (FNB) are commonly used for TKA surgeries but have been 
associated with quadricep weakness, and falls. Yu et al. (2016) conducted a Level III, therapeutic 
study comparing pain scores, narcotic use, mobilization, and in-hospital falls following 1,373 
unilateral TKA surgeries. Two techniques were compared: femoral nerve blocks using 
bupivacaine (n = 583) and periarticular blocks using liposomal bupivacaine (n = 527). The FNB 
group received 0.25% bupivacaine (20 mL) and an intraoperative injection of 0.25% bupivacaine 
(40 mL), 5 mL morphine and 30 mg ketorolac (1 mL). The LB group received 20 mL of LB (260 
mg) and 40 mL of normal saline.  
Results 
  Throughout LOS, pain scores were similar between both groups. Overall, the LB group 
consumed fewer opioids through POD 2 (p = .004). Seventy-seven patients in the LB group were 
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able to ambulate 100 feet before discharge, compared to sixty percent in the FNB group (p < 
.001). Ninety-four percent of patients in the LB group were able to climb the stairs compared to 
seventy-three percent in the FNB group (p < .001). In-hospital falls were lower in the LB group 
(0.6%) compared to the FNB group (2%), (p = .03). The results of this study demonstrated that 
liposomal bupivacaine provides comparable pain control that allows for decreased narcotic use. 
It also eliminates the need for an additional procedure and risk of nerve injury, quadricep 
weakness, and reduces the risk of falls. The authors of this study ultimately replaced FNBs with 
PAIs of LB for their TKA pain management protocol (Yu et al., 2016).  
Limitations  
The first limitation of this study was its retrospective approach. Another limitation was 
that it was historically controlled and the attrition bias was not corrected for. Lastly, twenty-four 
surgeons were involved in the administration of liposomal bupivacaine. Despite all surgeons 
receiving identical training, different techniques may have been used. The authors suggest that a 
large randomized trial be performed in the future (Yu et al., 2016).  
Kirkness, Asche, Ren, Kim, and Rainville (2016) 
Kirkness et al., (2016) organized a retrospective, single-site study involving 268 patients 
who underwent TKA. Two techniques were compared. The study group included patients who 
received Exparel via local infiltration during surgery (n = 134). The results were compared to a 
historical group that received a continuous femoral nerve block of bupivacaine via a pump 
between October 2011 and August 2013. The patients in the study group received 266 mg of 
liposomal bupivacaine (20 mL) combined with 30 mL of bupivacaine hydrochloride 0.25% and 
epinephrine. The patients in the historical cohort received 5 mg of hydrocodone bitartrate and 
325 mg of acetaminophen preoperatively. This group also received one of the following 
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combinations: ketorolac 60 mg, 0.2% ropivacaine (60 mL), morphine sulfate 4 mg and 
epinephrine 0.2 mg or, ketorolac 15-30 mg and 0.25% bupivacaine with epinephrine (60 mL) or, 
ketorolac 30 mg, 0.2% ropivacaine (10 mL) and 0.2 mg epinephrine. In addition to these 
combinations, 0.2% ropivacaine (400 mL) was administered via a pump.  
Results  
The results of this study demonstrated that 22% of patients who received LB were able to 
walk on the day of surgery, compared to 3% who received a FNB (p < .05). Pain scores and 
opioid use during the postoperative period were similar in both groups however, the liposomal 
bupivacaine group required less nonsteroidal anti-inflammatory drugs. Fifty percent of the 
patients in the study group were discharged within two days of surgery compared to nineteen 
percent in the control group (p < .001). On average, patients in the study group were able to walk 
6 meters on the day of surgery (DOS) compared to 3.1 meters in the control group (p < .001). On 
POD 1 the patients in the study group ambulated 53.7 meters compared to 25.5 meters (control 
group), p < .001). The average hospital length of stay was 3.1 days (study group) compared to 
3.6 days (control group), p < .03. The most significant benefit of using LB was significantly 
lower costs. The mean adjusted total direct hospital cost per patient in the LB group was $8,758 
versus $9,213 in the control group, a difference of $455 (p = .033) (Kirkness et al., 2016).  
Limitations  
The results from a small medical center may not be generalized to a broader population. 
This study did not follow the manufacturer's recommendations during the preparation of Exparel. 
The third limitation was that this study analyzed its findings and compared them to a historical 
cohort of patients. Potential issues with retrospective electronic medical record (EMR) analyses 
include missing data such as diagnoses and adverse events, as well as coding errors. This study 
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used propensity score matching that took into account demographic and clinical characteristics, 
age, sex, body mass index (BMI), and race. However, it did not take into account improvements 
in recovery pathways that may have impacted the LOS. The last limitation was that safety 
outcomes were not assessed (Kirkness et al., 2016).  
Singh et al. (2017)  
  A Level I meta-analysis was conducted by Singh et al. (2017) to evaluate the results of 
sixteen studies that took place over two years examining the results of periarticular liposomal 
bupivacaine for TKA. Primary outcome compared LOS. Secondary outcomes included analgesia 
requirements during the perioperative period, joint ROM, total perioperative opioid 
consumption, and postoperative pain scores. This meta-analysis compared several analgesic 
techniques such as knee infiltration of bupivacaine, femoral nerve block, multimodal systemic 
pain regimens, and other regional blocks (control groups), to immediate postoperative 
periarticular infiltration of LB into the knee joint (study group).  
Results  
In thirteen subgroups LB resulted in shorter LOS, compared to traditional TKA regimens 
including bupivacaine infiltration into the knee, femoral nerve block, multimodal regimens for 
systemic analgesia, and other regional blocks. Patients who received PAIs of Exparel had 0.17 
+/- 0.04 days shorter LOS (p < .001). LB was associated with 0.21 points greater pain relief on 
POD 1, while compared to the other groups overall. When sub-grouped, pain scores in the LB 
group were statistically similar in the FNB group. On POD 2, those who received periarticular 
injections of liposomal bupivacaine had better pain scores by 0.23 points. LB could not be 
analyzed regarding whether it reduced total opioid consumption and increased ROM because the 
sample size was too small. Overall, the infiltration of liposomal bupivacaine slightly shortens 
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LOS, especially compared to femoral nerve blocks. When compared to other analgesic therapies 
listed in this meta-analysis, liposomal bupivacaine provides marginally superior but sustained 
pain relief throughout POD 2. Although the price of LB is approximately $300 compared to 
bupivacaine ($2.50 to $8), three studies within this meta-analysis showed that LB was associated 
with decreased costs. The cost decrease could be due to faster discharge, fewer additional 
analgesic requirements, and decreased complications (Singh et al., 2017).  
Limitations  
Limitations of this study include the fact that there was no statistical significance for 
ROM, total opioid consumption, or POD 1 pain scores. Another limitation is that the subgroups 
did not differentiate the local anesthetic group from the liposomal bupivacaine group.  There was 
high heterogeneity when individual comparisons were done. Meta-regression and sensitivity 
analysis helped find the causes of heterogeneity. When this article was published an injection 
technique for Exparel was not yet established. The authors of this article recommend 
standardization of infiltration techniques, due to high heterogeneity (Singh et al., 2017).   
The use of bupivacaine versus LB in abdominal surgeries  
Hutchins et al. (2019) 
Hutchins et al. (2019) conducted a Level II prospective, randomized, blinded study 
examining the use of LB versus bupivacaine for transversus abdominis plane (TAP) blocks 
following robotic and laparoscopic hysterectomies. Patients in the experimental group (n = 31) 
received a bilateral TAP block consisting of 10 mL of 0.25% bupivacaine with 1:200,000 
epinephrine and 1.3% LB (10 mL) and normal saline (10 mL) on each side. Patients in the 
control group (n = 31) received sham TAP blocks using 30 mL of normal saline on each side 
preoperatively, followed by injections at each port site of 0.25% bupivacaine (10 mL) with 
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1:200,000 epinephrine before extubation. The primary outcome of this study was the total 
morphine equivalents within 72 hours of surgery. Secondary outcomes included: assessment of 
postoperative pain at 24,48, and 72 hours postop, PONV, length of recovery time, and 
complication rates.  
Results  
  Average morphine equivalents were lower in the experimental group over the course of 
72 hours following surgery (20.8 mg versus 25 mg), (p = .03). In both groups, narcotic use was 
highest within 24 hours of surgery. There was less difference in narcotic requirements between 
both groups on POD 2 and 3. Five patients in the experimental group (16.1%) were opioid-free at 
72 hours postop, compared to zero patients in the control group. Overall, the patients in the 
experimental group had decreased total maximal pain scores throughout days 1 through 3 (p = 
.022). Patient satisfaction, length of PACU or hospital stay, and PONV were similar between 
groups (Hutchins et al., 2019).  
Limitations  
Specific strategies, such as the number of port sites, were not standardized. The 
infiltration technique was detailed in the protocol, however compliance was not measured. 
Another limitation that could have potentially impacted outcomes was that the control group 
received 100 to 125 mg of bupivacaine whereas, the experimental group received 50 mg of 
bupivacaine and 266 mg of LB. The saline injection during the sham TAP procedure could have 
inadvertently caused pain. Lastly, this study relied on patients reporting their pain, due to the fact 
most were treated as outpatients. The authors suggest that future studies blind the reporter and 
the observer (Hutchins et al., 2019).  
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Hutchins, Kesha, Blanco, Dunn, and Hochhalter (2016) 
A prospective, randomized, observer-blinded study was performed by Hutchins et al., 
(2016) that compared TAP blocks using liposomal bupivacaine and TAP blocks using non-
liposomal bupivacaine in patients undergoing donor nephrectomies. Patients were randomized to 
receive TAP blocks using 1.3% liposomal bupivacaine and normal saline (n = 30) or 0.25% 
bupivacaine with adrenaline (n = 29).  
Results  
There were no differences in maximal postoperative pain scores between 0 to 24 hours or 
24 to 48 hours. Maximal pain scores in the LB group were 5 versus the non-LB group (6) at 24-
48 hours postop (p = .009). At 48-72 hours postop, maximal pain scores in the LB group was 3 
versus the non-LB group (5) (p = .02). Opioid use, measured in fentanyl equivalents, were lower 
in the LB group (105 mcg) versus 182 mcg in the non-LB group (p = .03). Seven patients in the 
LB group experienced PONV within 72 hours, compared to fifteen patients in the non-LB group 
(p = .03). The average length of stay (in hours) was 67.7 in the LB group compared to 78.1 in the 
non-LB group (p = .02). LB was associated with better pain control, less PONV, and decreased 
LOS (Hutchins et al., 2016).  
Limitations  
The anesthetist in charge of performing the TAP block was not blinded. Postoperative 
analgesic administration of ketorolac and opioids were administered as needed rather than 
scheduled. Another limitation was that patient satisfaction was not measured. The authors 
recommend that more randomized multicenter trials be completed in the future to confirm the 
results of this study. Future studies should also compare LB to other long-acting local anesthetics 
that are currently being developed (Hutchins et al., 2016).  
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Barron et al. (2017) 
  A single-center, double RCT was conducted by Barron et al. (2017) involving fifty-nine 
patients who underwent laparoscopic hysterectomies.  The objective of this study was to 
determine whether or not a pre-incision injection of LB (266 mg) provided better pain relief than 
0.25% bupivacaine (50 mg) following surgery. Each group consisted of thirty-two patients. The 
primary outcome was overall average pain scores via telephone survey on POD 3. Secondary 
outcomes included overall average and worst pain scores on POD 1, 2 and 14, in-hospital pain 
scores, and total narcotic usage.  
Results  
The LB group had decreased average pain scores on POD 3 (p = .02). The LB group also 
reported lower worst pain scores on POD 2 (p = .03) and POD 3 (p = .01). No differences existed 
for opioid use, length of stay, adverse effects, in-hospital pain scores, or pain scores on POD 1 or 
POD 14. The authors do not support the routine use of LB for port site analgesia in laparoscopic 
or robotic hysterectomies (Barron et al., 2017).  
Limitations   
  The authors of this study did not list any limitations.  
Stokes et al. (2017) 
  Stokes et al. (2017) conducted a retrospective cohort study to examine the effects of LB 
for TAP blocks on postoperative pain and opioid consumption following colorectal surgery. The 
non-LB group received 0.25% bupivacaine (20 mL) on both sides of the incision (n = 104). The 
LB group received 10 mL of LB and 10 mL of saline (20 mL) on both sides of the incision (n = 
303).  
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Results  
  Average pain scores at all times up to 24 to 36 hours were lower in the LB group 
compared to the non-LB group (4.8 versus 5.5) (p = .031). Between 36 to 48 hours postop both 
groups had similar pain scores (p = .120). Patients in the LB group required fewer intravenous 
opioids (64.5 versus 99), (p = .04). Oral opioid requirements were not significantly different 
between both groups, (p = .449). Acetaminophen use was similar between both groups (p = 
.219). Patients in the LB group required less ketorolac (99.1 versus 145.7 mg), (p = .006). LOS 
and cost were not significantly different between both groups. LOS in the non-LB group (5.6 d 
versus 6.3 d), (p = .274). The cost of the LB group totaled $24,553.46 versus $21,912.52 in the 
non-LB group, (p = .560) (Stokes et al., 2017).  
Limitations  
This study was retrospective and had a single-center design. There was also heterogeneity 
in the administration of blocks. The authors recommend additional studies be completed to 
examine the cost-effectiveness of LB (Stokes et al., 2017).  
Guerra et al. (2019) 
Guerra et al. (2019) conducted a Level III retrospective, comparative study involving 100 
patients undergoing elective laparoscopic colectomies. Fifty patients received liposomal 
bupivacaine via TAP blocks (study group). The study group was compared to a retrospective 
group of fifty patients who received bupivacaine via the TAP block (control group). Outcomes 
included narcotic requirements during hospitalization, number of days until ambulation, number 
of days until bowel function, and total hospital LOS.  The patients in the control group received 
0.25% bupivacaine (80 mL). The patients in the study group received liposomal bupivacaine (20 
mL), plain bupivacaine (40 mL), and sterile saline (20 mL).  
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Results  
The study group required fewer narcotics (5.06 versus 18.75 mg), (p = .0002). Sixteen 
patients (32%) in the study group did not require any narcotics postoperatively during their 
hospital stay, compared to four patients (8%) in the control group, (p = .005).  The study group 
had an earlier return of bowel function (1.7 versus 2.4 days), (p = .0002). The study group had 
shorter LOS (2.7 versus 5.4 days), (p = .0146). Time to ambulate was shorter in the study group 
(0.9 versus 1.3 days), although insignificant, (p = .0521).  
Limitations  
Several limitations exist in this study. The surgeons were not blinded. The sample size 
was somewhat small. Data was collected from two different groups of patients who were 
assessed at different times. The authors recommend a larger sample size with more focus on cost 
analysis.  
Robertson et al. (2019) 
Robertson et al. (2019) conducted a retrospective chart analysis. Patients either received 
TAP blocks preoperatively and rescue opioids (TAP group) or PCA only (PCA group). The 
purpose of this study was to compare TAP blocks using LB before laparoscopic sleeve 
gastrectomy (LSG) and laparoscopic gastric bypass (LRYGB). The primary outcome was 
narcotic requirements (morphine equivalents).  
Results  
The TAP group required significantly less opioids (p = < 0.0001). The average length of 
stay was 2 days in the PCA group, compared to 1 day in the TAP group (p = < 0.0001).  Pain 
scores during the immediate postoperative period and 12 hours postop were significantly higher 
in the TAP LRYGB group compared to the PCA LRYGB group (p = < 0.05). Pain scores were 
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significantly higher immediately after surgery in the PCA LSG group versus the PCA LSG group 
(p = .0109) (Robertson et al., 2019).  
Limitations  
This study is retrospective and not randomized. The TAP group received intravenous 
narcotics as needed and the PCA group did not. This could have affected narcotic consumption. 
The authors recommend that future research adheres to strict pain assessment methods 
(Robertson et al., 2019). 
Discussion  
Fifteen articles were included in this paper that compare the outcomes of Exparel versus 
bupivacaine. Of these fifteen articles, twelve focused on the use of liposomal bupivacaine in 
periarticular injections versus traditional periarticular injections. Two of these articles supported 
the use of Exparel over bupivacaine. One article credited Exparel for lowering pain scores, 
decreasing total opioid consumption, extending time to first postoperative narcotic rescue, and 
allowing for more opioid-free patients upon discharge. Another article credited Exparel for 
decreasing LOS and providing greater pain relief on POD 1. Eight articles did not recommend 
the use of Exparel over bupivacaine. Some reasons Exparel was not recommended include no 
differences in LOS, patient satisfaction, PONV, or other complications. Several studies stated 
that the results did not justify the high cost. Bagsby et al., (2014) suggested that Exparel might be 
associated with increased pain from 24 hours postop throughout the hospital stay. Two studies 
listed findings that supported and rejected the use of Exparel. These studies did not directly state 
whether the use of Exparel in TKA surgeries was warranted.   
  Two articles compared the use of Exparel injections versus FNBs. Both of these articles 
supported the use of Exparel. The results of these studies showed that periarticular injections of 
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Exparel resulted in decreased opioid usage, better ambulation, decreased falls, faster ambulation, 
decreased LOS, and ultimately decreased costs. 
Six studies examining the outcomes associated with LB TAP blocks in various abdominal 
surgeries were included in this literature review. Five of the six studies compared LB to 
bupivacaine. One study compared TAP blocks using LB to patient-controlled analgesia (PCA). 
Five studies supported the use of LB due to its positive outcomes including improved pain 
control, decreased PONV, decreased LOS, decreased opioid requirements, quicker return of 
bowel function, and decreased time to ambulation without an identifiable cost increase. The use 
of LB was associated with more opioid-free patients at 72 hours postop (Stokes et al., 2017).  
Barron et al. (2017) did not support the routine use of LB for port-site analgesia in 
laparoscopic or robotic surgeries. This study found that LB was associated with decreased 
average pain on POD 3 however, it did not find any differences in opioid consumption or quality 
of life.  
  It is difficult to determine the efficacy of LB since pain is highly subjective among 
individuals.  The studies discussed throughout this manuscript are highly variable, making it 
difficult to compare results. Many studies use an assortment of pain medications as adjuncts 
throughout the postoperative period to treat breakthrough pain.  
Various techniques for PAIs are used, which could potentially alter the outcomes. There 
is also a lack of consistency regarding supplemental medications added to the PAIs. Adjuncts 
include ropivacaine, epinephrine, ketorolac, and clonidine. The timing of medication 
administration is highly variable. In some of the TKA studies, LB is not injected until after the 
site is closed. This means it is not injected into the posterior capsule or periosteum. Some articles 
compare LB outcomes in patients who received spinal anesthesia versus general anesthesia but 
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do not seem to take into account the differences in outcomes that may be associated with the type 
of anesthesia used.  
Alijanipour et al. (2017) assessed pain at the same times each day, in all patients, 
regardless of the time of surgery, physical therapy, or administration of pain medications. This 
could result in a misinterpretation of outcomes. Many studies state that the surgeons were not 
blinded when injecting the local anesthetics. Data for use of LB in TAP blocks is variable 
because several different types of abdominal surgeries were examined, including laparoscopic 
and robotic hysterectomy, laparoscopic sleeve gastrectomy, laparoscopic gastric bypass, donor 
nephrectomy, and other colorectal surgeries. More studies should be conducted to examine the 
use of LB on each of these abdominal surgeries to better understand the associated outcomes. All 
of these factors have the potential to alter the results.  
In many studies, Exparel was shown to be more efficacious in TKA by allowing for 
better ambulation, decreased falls, and faster ambulation compared to FNB. Many studies did not 
support the use of Exparel while comparing cost versus benefit.   
Conclusion 
  These articles have listed several recommendations for future studies. Some of these 
recommendations include larger sample sizes, standardized injection techniques, protocols for 
managing breakthrough pain, and longer follow-up periods. Other ways to improve future studies 
include determining a standard number of port sites for laparoscopic surgeries, determining a 
standardized protocol whether postoperative analgesics will be administered as needed or on a 
scheduled basis, and administering the same drugs and doses of supplemental analgesics to the 
control and study groups.  
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